INTRODUCTION
Proteoglycans are defined as macromolecules containing at least one glycosaminoglycan chain covalently bound to a core protein. They have, been identified in a broad spectrum of tissues and have been proposed to participate in a multitude of functions in the cells and tissues as a result of their polymorphism (for reviews see refs. [1] and [2] ). Glycosaminoglycans have long been known to be present in platelets, and their distribution mainly in a-granules as well as on surface membranes has been demonstrated [3, 4] . An interaction between platelet proteoglycan (P.PG) and platelet factor 4 has been demonstrated, and it has been postulated that one possible role of P.PG is the 'packaging' of platelet factor 4 in platelet a-granules [5] . The P.PG might therefore be a platelet factor 4 carrier for delivery to sites of blood-vessel injury. An inhibitor of complement subcomponent Clq has been identified in human serum as to be proteoglycan [6] . On the basis of the nature and the size of their glycosaminoglycan side chains, the proteoglycans involved in these two functions might be related despite the fact that average molecular masses appeared to be somewhat different; this observation could be the result of partial degradation during the preparations. P.PG has recently been obtained from freshly prepared human platelets and partially characterized [7] as a 136 kDa molecule containing four chondroitin 4-sulphate chains, each with an apparent molecular mass of 28 kDa. This P.PG was very similar to the Clq inhibitor previously characterized. It is therefore likely that P.PG acts as a Clq inhibitor in addition to being a carrier of platelet factor 4 [5] [6] [7] . Despite the importance of the two above-mentioned biological roles, a molecular study of P.PG protein core is still lacking. The determination of the protein structure of P.PG seemed to us to be a prerequisite in the elucidation of its possible functions. 20 'C. The platelet pellet was washed three times with 100 ml of 0.9 % NaCl/0.33 % EDTA before extraction of P.PG. This was carried out for 3 h at 4 'C in 100 ml of 4 Mguanidinium chloride/50 mM-sodium acetate buffer, pH 5.8, containing 5 mM-benzamidine, 10 mM-6-aminohexanoic acid and 10 mM-EDTA as proteinase inhibitors. Solid CsCl was added to the extract up to a density of 1.4 g/ml and the mixture was submitted to densityAbbreviations used: P.PG, platelet proteoglycan; PG19, rat yolk-sac tumour proteoglycan.
EXPERIMENTAL
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Vol. 255 gradient centrifugation (35000 rev./min in a Beckman L8-55 ultracentrifuge, 60 Ti rotor, for 40 h at 20°C); the P.PG-containing fraction was recovered in the bottom quarter of the centrifuge tube. It was exhaustively dialysed against 7.6 M-urea/50 mM-Tris/HCl buffer, pH 7.6 (buffer A), at 4 'C. This dialysis method was less efficient in desalting when compared with the classical dialysis method against water, but allowed the material to be maintained in a soluble state. The dialysed P.PG fraction was directly applied to a DEAE-Sepharose CL-6B column (12 cm x 1.5 cm) equilibrated in buffer A. The column was successively washed with buffer A (30 ml), then with buffer A containing 0.2 M-NaCl (50 ml), and the elution ofP.PG was achieved with buffer A containing 1 M-NaCl (flow rate 20 ml/h). The 1 M-NaCl-eluted fraction was made 0.2 M with respect to NaCl by a 5-fold dilution with buffer A and was directly applied to a Mono Q HR 5/5 column equilibrated in buffer A containing 0.2 M-NaCl. Elution was performed with a linear 95 ml NaCl gradient (0.2-1 M) in buffer A (flow rate 0.5 ml/min); the P.PG-containing fractions were exhaustively dialysed against distilled water at 4 'C and dried under vacuum.
Characterization of the platelet proteoglycan Superose 6 gel filtrations of P.PG were carried out with 0.15 M-NaCl/50 mM-Tris/HCl buffer, pH 7.6 (buffer B) as eluent, whereas 4 M-guanidinium chloride/50 mmsodium acetate buffer, pH 5.8 (buffer C), was used for the gel filtration of the chondroitinase-treated P.PG (P.PG core) on the same chromatographic medium (HR 10/30 column, flow rate 0.5 ml/min).
Polyacrylamide [12] . Deglycosylation in HF/pyridine was carried out for 4 h at 20°C under N2 [13] . RESULTS 
Purification of the platelet proteoglycan
The platelets were completely solubilized in 4 Mguanidinium chloride/50 mM-sodium acetate buffer, pH 5.8, containing proteinase inhibitors. Upon CsCl addition up to a density of 1.4 g/ml the extract became cloudy and a substantial gel formed at the top of the centrifuge tube during the density-gradient centrifugation. About 80 % of the hexuronate was recovered in the bottom quarter of the tube after this step. After extensive dialysis against buffer A at 4°C no precipitation occurred, and the material was directly applied to a DEAE-Sepharose CL-6B column equilibrated in the same buffer. The elution was achieved by a two-step procedure (Fig. 1) ; approx. 10 % of the hexuronate was eluted in the 0.2 M-NaCl fraction and 40 % was recovered in the 1 M-NaCl fraction. About 50 % of the applied hexuronates was not bound to the column; this observation might be due to partial inhibition of binding to the DEAE-Sephadex column as a result of the dialysis conditions (see the Experiment section). (Fig. 1) containing peak coinciding with a 280 nm-absorbing peak; the hexuronate recoveries ranged between 95 and 98 % for the different P.PG fractions during this step.
The partition coefficients Kav. were 0.30,0.27,0.24 and 0.22
for fractions I, II, III and IV respectively. The hexuronate/ A280 ratio increased from fraction I to fraction IV: it was 3.6-fold higher for fraction IV than for fraction I. On polyacrylamide/agarose-gel electrophoresis the mobility decreased from fraction I to fraction IV (Fig. 4a ). These observations suggest that P.PG is polydisperse; the polydispersity is reflected by the retention on the Mono Q HR 5/5 column, indicating a charge heterogeneity. The latter is accompanied by a shift in the The fractions isolated after ion-exchange chromatography on the Mono Q column (Fig. 2) (Fig. 5a ). It was estimated at 27 kDa after chondroitinase ABC treatment, whereas it was 24 kDa after chondroitinase AC digestion; in both cases a faint diffuse band was observed below the major one. A sample treated with a mixture of the two chondroitinases gave rise to the 24 kDa band. After HF/pyridine treatment the P.PG core was characterized as a major 20 kDa compound; a minor band was also detected as a smear with an approximate apparent molecular mass of 17 kDa (Fig.  5b) . When HF/pyridine treatment was performed on a previously chondroitinase ABC-treated P.PG the same major band (20 kDa) was still detected. These results suggest that the P.PG core apparent molecular mass does not exceed 20 kDa; the existence of a compound of a slightly smaller size is indicated as a smear.
N-Terminal sequence of P.PG. The purification of the P.PG protein core obtained after chondroitinase ABC treatment was achieved by Superose 6 gel filtration with buffer C as eluent. Under these conditions the P.PG protein core was eluted as a symmetrical peak with a Kav value of 0.60, whereas non-treated P.PG was eluted with a Kav of 0.21 (Fig. 6) . The totality of the 280 nmabsorbing material was recovered in the 0.60 Kav. peak when compared to the non-treated P.PG. The amino The identity of the P.PG protein core in fractions I, II, III and IV was demonstrated after chondroitinase ABC digestion. A major gel-penetrating band common to all the four digested samples was characterized on SDS/ polyacrylamide-gel electrophoresis by Coomassie Blue staining (Fig. 4b) ; non-digested samples did not give rise to any gel-penetrating band under these conditions. No material could be detected above the major band in any sample when the gels were stained with Coomassie Blue or Toluidine Blue. An additional faint and diffuse band (band X in Fig. 4b ) could, however, be detected by Coomassie Blue staining, just below the major one, mainly in the digests of fractions III and IV. This result indicates that the protein cores of P.PG in fractions I, II, III and IV have an identical size, but the minor component (band X) might represent a second core protein, as discussed below. Therefore the subsequent experiments dealing with P.PG molecular characterization were performed on pooled fractions I, II, III and IV further purified on Superose 6 in order to remove any low-molecular-mass 280 nm-absorbing material (Fig. 6a) . acid compositions of P.PG and of its Superose 6-purified core are presented in Table 1 ; glycine, serine, aspartic acid and glutamic acid were predominant amino acids. The Superose ABC core (chondroitinase ABC-treated P.PG, purified by Superose 6 gel filtration, K., 0.60) was Vol. 255 Chondroitinase ABC-treated P.PG was submitted to SDS/polyacrylamide-gel electrophoresis, and the 27 kDa band and the diffuse smear below were excised without staining and electroeluted. After dialysis against distilled water the materials were solubilized in 4 M-guanidinium chloride and precipitated with cold ethanol. The 27 kDa band was homogeneous upon sequencing, and its Nterminal amino acid sequence was determined up to residue 41 (Fig. 7) . The N-terminal amino acid sequence of the material excised in the smear below the 27 kDa band (band X in Fig. 4b ) was determined up to residue 21 (Fig. 7) .
After CNBr treatment of P.PG, one major peak (CNI) was isolated by Superose 6 gel filtration in buffer C with a Kd value identical with that of native P.PG (Fig. 6c) . The N-terminal amino acid sequence of this fragment was determined up to residue 24 (Fig. 7) . This peptide overlaps the two previously characterized N-terminal sequences in the P.PG preparations, demonstrating that the DLFPK... sequence begins in fact at position 46 in the 27 kDa protein core of P.PG.
DISCUSSION
Platelet proteoglycan was isolated in a degree of purity allowing the characterization of the structure of its [7] (16-20 kDa). On the other hand the amino acid composition of the isolated P.PG in the present work is in good agreement with the data of Okayama et al. [7] , suggesting that the P.PG that we have isolated is identical with their preparation.
The N-terminal amino acid sequence of-P.PG was deduced from the three overlapping sets of sequence data presented in the Results section (the intact P.PG, the {CN1 fragment and band X). When (Fig. 7) . We have indicated that during its extraction P.PG is shortened in its Nterminal region, the first 45 amino acid residues being split off at a position very close to the cleavage site of the propeptide in PG19. This observation raises the possibility that the first 45 amino acid residues in P.PG in fact consist of a core propeptide that is partially removed after lysis of the platelets. We possess evidence that a Ser-Gly repeated structure exists in P.PG as in PG19, its length being apparently shorter in the former (J.-P. Perin, F. Bonnet, P. Maillet & P. Jolles, unpublished work).
In conclusion, in human platelets a chondroitin sulphate proteoglycan has been characterized whose protein core is of relatively small size; it could be a representative of a widespread class of the proteoglycan family that could be synthesized as a pre-form before exposure to the extracellular medium.
